David Tetard

Dr. David Tetard


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Metallomics
Verified
Journal Article
Open access
PDF file
DWDavid G. Workman
David G. Workman
ATAndrew Tsatsanis
Andrew Tsatsanis
FLFrank W. Lewis
Frank W. Lewis
JBJohn P. Boyle
John P. Boyle
MMMaryam Mousadoust
Maryam Mousadoust
JDJames A. Duce
James A. Duce
We report that novel 1-hydroxypyridin-2-ones show comparable neuroprotective results to deferiprone in a cell culture model of Parkinson's disease.

1 January 1995 in Journal of the Chemical Society, Chemical Communications
Verified
Journal Article
Closed access
PDF file
DTDavid Tetard
David Tetard
ARAlain Rabion
Alain Rabion
JVJean-Baptiste Verlhac
Jean-Baptiste Verlhac
JGJean Guilhem
Jean Guilhem
A binuclear manganese (II/II) complex with a µ-hydroxo bridging ligand catalyses the hydroxylation of cyclohexane in the presence of tart-butyl hydroperoxide (TBHP).

1 July 2016 in Journal of Inorganic Biochemistry
Verified
Journal Article
Open access
DWDavid G. Workman
David G. Workman
MHMichael Hunter
Michael Hunter
LDLynn Dover
Lynn Dover
DTDavid Tetard
David Tetard
Several novel chelators based on 1-hydroxy-2(1H)-pyridinone coordinating groups decorating a triaza macrocyclic backbone scaffold were synthesised as potential powerful Fe(3+) chelators capable of competing with bacterial siderophores. In particular, a novel chloromethyl derivative of 1-hydroxy-2(1H)-pyridinone exploiting a novel protective group for this family of coordinating groups was developed. These are the first examples of hexadentate chelators based on 1-hydroxy-2(1H)-pyridinone to be shown to have a biostatic activity against a range of pathogenic bacteria. Their efficacy as biostatic agents was assessed revealing that minor variations in the structure of the chelator can affect efficacy profoundly. The minimal inhibitory concentrations of our best tested novel chelators approach or are comparable to those for 1,4,7-tris(3-hydroxy-6-methyl-2-pyridylmethyl)-1,4,7-triazacyclononane, the best Fe(3+) chelator known to date. The retarding effect these chelators have on microbial growth suggests that they could have a potential application as a co-active alongside antibiotics in the fight against infections.

1 January 1995 in Journal of the Chemical Society, Chemical Communications
Verified
Journal Article
Closed access
PDF file
MDMichel Delroisse
Michel Delroisse
ARAlain Rabion
Alain Rabion
FCFrançoise Chardac
Françoise Chardac
DTDavid Tetard
David Tetard
JVJean-Baptiste Verlhac
Jean-Baptiste Verlhac
JSJean-Louis Séris
Jean-Louis Séris
Di-µ-oxo dimanganese(III/IV) complexes are efficient catalysts for H2O2 disproportionation in neutral aqueous medium; the activity can be correlated to the electron density on the metal and the accessibility of the catalytic site.

1 November 1996 in Journal of Molecular Catalysis A: Chemical
Verified
Journal Article
Closed access
DTDavid Tetard
David Tetard
JVJean-Baptiste Verlhac
Jean-Baptiste Verlhac

26 June 2019 in Investigational New Drugs
Verified
Journal Article
Open access
PDF file
SKSotiris Kyriakou
Sotiris Kyriakou
MMMelina Mitsiogianni
Melina Mitsiogianni
TMTheodora Mantso
Theodora Mantso
WCWilliam Cheung
William Cheung
Stephen TodrykStephen Todryk
Stephen Todryk
Mihalis PanayiotidisMihalis Panayiotidis
Mihalis Panayiotidis
Summary: The anticancer activity of a series of novel synthesized, hydroxypyridone-based metal chelators (analogues of L-mimosine) was evaluated in an in vitro model of melanoma consisting of malignant melanoma (A375), non-melanoma epidermoid carcinoma (A431) and immortalized non-malignant keratinocyte (HaCaT) cells. More specifically, we have demonstrated that the L-enantiomer of a methylated analogue of L-mimosine (compound 22) can exert a potent anticancer effect in A375 cells when compared to either A431 or HaCaT cells. Moreover, we have demonstrated that this analogue has the ability to i) promote increased generation of reactive oxygen species (ROS), ii) activate both intrinsic and extrinsic apoptosis and iii) induce perturbations in cell cycle growth arrest. Our data highlights the potential of compound 22 to act as a promising therapeutic agent against an in vitro model of human malignant melanoma.